MyAverix Finance MyAverix Finance

F · Healthcare

CENTESSA PHARMACEUTICALS (260)

Biotechnology

CENTESSA PHARMACEUTICALS (260) is listed on F in the Healthcare sector. Industry: Biotechnology. As of 2026-03-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 260

P/E ratio
18.00

CENTESSA PHARMACEUTICALS (260) — FAQ

What is 260's P/E ratio?

The price-to-earnings (P/E) ratio for CENTESSA PHARMACEUTICALS (260) is 18.00 (data as of 2026-03-23).

Does CENTESSA PHARMACEUTICALS pay a dividend?

Dividend yield is not available in the current snapshot for CENTESSA PHARMACEUTICALS (260). Check the MyAverix Finance app for the latest dividend data.

What sector is CENTESSA PHARMACEUTICALS in?

CENTESSA PHARMACEUTICALS (260) is classified in the Healthcare sector (Biotechnology industry).

What exchange is 260 listed on?

260 is listed on F.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play